Is PayPal Stock Finally a Buy?
Shares of online payment giant PayPal (NASDAQ:PYPL) have struggled over…
Sell
48
PTGX Quote, Financials, Valuation and Earnings
Last price:
$82.82
Seasonality move
:
7.36%
Day range:
$76.70 - $80.75
52-week range:
$33.31 - $93.25
Dividend yield:
0%
P/E ratio:
125.60x
P/S ratio:
24.39x
P/B ratio:
7.70x
Volume:
882.4K
Avg. volume:
1.4M
1-year change:
67.07%
Market cap:
$5B
Revenue:
$434.4M
EPS (TTM):
$0.63
Analysts' Opinion
-
Consensus RatingProtagonist Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $89.77, Protagonist Therapeutics, Inc. has an estimated upside of 7.45% from its current price of $79.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 18.28% downside risk from its current price of $79.54.
Fair Value
-
According to the consensus of 9 analysts, Protagonist Therapeutics, Inc. has 7.45% upside to fair value with a price target of $89.77 per share.
PTGX vs. S&P 500
-
Over the past 5 trading days, Protagonist Therapeutics, Inc. has overperformed the S&P 500 by 2.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Protagonist Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protagonist Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Protagonist Therapeutics, Inc. reported revenues of $4.7M.
Earnings Growth
-
Protagonist Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Protagonist Therapeutics, Inc. reported earnings per share of -$0.62.
Enterprise value:
4.4B
EV / Invested capital:
6.72x
Price / LTM sales:
24.39x
EV / EBIT:
231.86x
EV / Revenue:
21.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
69.17x
Price / Operating cash flow:
80.10x
Enterprise value / EBITDA:
214.81x
Gross Profit (TTM):
$207.7M
Return On Assets:
6.54%
Net Income Margin (TTM):
21.94%
Return On Equity:
7.15%
Return On Invested Capital:
7.03%
Operating Margin:
-985.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $323.8M | $209.2M | $4.7M | $4.7M | |
| Gross Profit | -$2.7M | $320.6M | $207.7M | $4M | $4.4M | |
| Operating Income | -$153.2M | $149.1M | $19M | -$41.5M | -$46.4M | |
| EBITDA | -$150.5M | $152.3M | $20.5M | -$40.8M | -$46.1M | |
| Diluted EPS | -$2.61 | $2.67 | $0.63 | -$0.54 | -$0.62 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $327.7M | $276.6M | $324.9M | $476.8M | $586.4M | |
| Total Assets | $373.2M | $282.2M | $330M | $603.9M | $701.7M | |
| Current Liabilities | $39.2M | $36.8M | $27.9M | $44.6M | $44.9M | |
| Total Liabilities | $43.5M | $38.6M | $27.9M | $71.9M | $56.3M | |
| Total Equity | $329.7M | $243.6M | $302.1M | $531.9M | $645.4M | |
| Total Debt | $6.3M | $1.8M | -- | $10.9M | $8.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$118.8M | $230.3M | $65.5M | -$27.9M | -$1.9M | |
| Cash From Investing | $26M | -$352M | -$106.9M | -$208.7M | -$58.6M | |
| Cash From Financing | $170.5M | $22.3M | $24.1M | $12.1M | $5.7M | |
| Free Cash Flow | -$119.5M | $229.2M | $63.7M | -$28.6M | -$2M | |
PTGX
Sector
Market Cap
$5B
$28.8M
Price % of 52-Week High
85.3%
49.55%
Dividend Yield
0%
0%
Shareholder Yield
-0.59%
-1.29%
1-Year Price Total Return
67.07%
-24.88%
Beta (5-Year)
2.216
0.575
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$77.85
200-day SMA
Buy
Level
$53.40
Bollinger Bands (100)
Buy
Level
52.33 - 70.73
Chaikin Money Flow
Buy
Level
81.2M
20-day SMA
Buy
Level
$76.88
Relative Strength Index (RSI14)
Buy
Level
61.60
ADX Line
Buy
Level
55.51
Williams %R
Sell
Level
-15.7757
50-day SMA
Buy
Level
$68.54
MACD (12, 26)
Buy
Level
2.79
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
174M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.6957)
Buy
CA Score
(Annual)
Level (3.8157)
Sell
Beneish M-Score
(Annual)
Level (6.5501)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-11.7648)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Stock Forecast FAQ
In the current month, PTGX has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PTGX average analyst price target in the past 3 months is $89.77.
-
Where Will Protagonist Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protagonist Therapeutics, Inc. share price will rise to $89.77 per share over the next 12 months.
-
What Do Analysts Say About Protagonist Therapeutics, Inc.?
Analysts are divided on their view about Protagonist Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protagonist Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Protagonist Therapeutics, Inc.'s Price Target?
The price target for Protagonist Therapeutics, Inc. over the next 1-year time period is forecast to be $89.77 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PTGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protagonist Therapeutics, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTGX?
You can purchase shares of Protagonist Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protagonist Therapeutics, Inc. shares.
-
What Is The Protagonist Therapeutics, Inc. Share Price Today?
Protagonist Therapeutics, Inc. was last trading at $82.82 per share. This represents the most recent stock quote for Protagonist Therapeutics, Inc.. Yesterday, Protagonist Therapeutics, Inc. closed at $79.54 per share.
-
How To Buy Protagonist Therapeutics, Inc. Stock Online?
In order to purchase Protagonist Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PTGX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PTGX
Sector
P/E ratio
125.60x
23.09x
PEG ratio
--
-0.01x
P/B ratio
7.70x
1.84x
Price / LTM sales
24.39x
1.58x
Growth Metrics
PTGX
Sector
Revenue growth
0.79%
5.49%
Earnings growth
-14.73%
2.22%
Revenue (5-year growth)
351.71%
6.46%
Earnings forecast
-$0.64
-$0.20
Profitability
PTGX
Sector
Profitability FY 2024
$431.5M
$3.8M
Return on invested capital
7.03%
-30.03%
Return on assets
6.54%
-27.12%
Return on equity
7.15%
-35.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
20
Estimated Next Earnings Date
Feb
5
Balance Sheet
PTGX
Sector
Total cash
$576.1M
$28.1M
Short term investments
$321.7M
$26M
Total assets
$746.8M
$80.8M
Long term debt
$8.5M
$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Sprouts Stock Fall So Much?
Shares of health-oriented grocery chain Sprouts Farmers Market (NASDAQ:SFM) have…
Why Did Amazon Go Up So Much?
Shares of Amazon (NASDAQ:AMZN) soared late last week, bringing the…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Alerts
Buy
100
GMED alert for Nov 10
Globus Medical, Inc. [GMED] is up 1.84% over the past day.
Buy
73
GCT alert for Nov 10
GigaCloud Technology, Inc. [GCT] is up 1.06% over the past day.
Buy
84
FROG alert for Nov 10
JFrog Ltd. [FROG] is up 7.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
